Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

304.99 +8.58 (+2.89%)
Streaming Delayed Price Updated: 11:04 AM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biogen Idec

< Previous 1 2 3 4 Next >
Biogen and the Biogen Foundation Commit $500,000 in Support to Address COVID-19 in India and Around the World
SOURCE: Biogen 
Via 3BL Media
Exposures COVID-19
Biogen Ranks #17 on 100 Best Corporate Citizens of 2021
SOURCE: Biogen 
Via 3BL Media
Topics Climate Change
Exposures Climate
Biogen, Americares and Harvard Chan C-CHANGE Help Community Health Clinics Address Climate Risks
SOURCE: Biogen 
Via 3BL Media
Biogen Employees Engage in a Week-Long Series of Open Dialogues to Enhance DE&I Understanding
SOURCE: Biogen 
Via 3BL Media
Topics Climate Change
Exposures Climate
Biogen Receives Honorable Mention From Fast Company's World Changing Ideas Awards
SOURCE: Biogen 
Via 3BL Media
Topics Supply Chain
Exposures Supply Chain
Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics
SOURCE: Biogen 
Via 3BL Media
Topics Emissions
Exposures COVID-19 Climate
New Project to Help Community Health Clinics Address Climate Risks Launched by Biogen, Americares and Harvard Chan C-CHANGE
SOURCE: Biogen 
Via 3BL Media
Topics Climate Change
Exposures Climate
WBCSD Member Companies Launch New Project to Advance Global Health and Wellbeing
SOURCE: Biogen 
Via 3BL Media
Topics Death
Exposures COVID-19 Death
Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026
Via FinancialNewsMedia
Topics Death
Exposures COVID-19 Death
The Road to a 100% Electric Vehicle Fleet
SOURCE: Biogen 
Via 3BL Media
Topics Electric Vehicles
Exposures Electric Vehicles
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.